Cited by 862Amyotrophic Lateral Sclerosis ResearchAmyloidosis: Diagnosis, Treatment, OutcomesNeurogenetic and Muscular Disorders Research

Global Epidemiology of Amyotrophic Lateral Sclerosis: A Systematic Review of the Published Literature

Open access
Chiò, A., Logroscino, G., Traynor, B.J., Collins, J., Simeone, J.C., Goldstein, L.A., White, L.A.·2013·Neuroepidemiology

Abstract

Background: Amyotrophic lateral sclerosis (ALS) is relatively rare, yet the economic and social burden is substantial. Having accurate incidence and prevalence estimates would facilitate efficient allocation of healthcare resources. Objective: To provide a comprehensive and critical review of the epidemiological literature on ALS. Methods: MEDLINE and EMBASE (1995-2011) databases of population-based studies on ALS incidence and prevalence reporting quantitative data were analyzed. Data extracted included study location and time, design and data sources, case ascertainment methods and incidence and/or prevalence rates. Medians and interquartile ranges (IQRs) were calculated, and ALS case estimates were derived using 2010 population estimates. Results: In all, 37 articles met the inclusion criteria. In Europe, the median incidence rate (/100,000 population) was 2.08 (IQR 1.47-2.43), corresponding to an estimated 15,355 (10,852-17,938) cases. Median prevalence (/100,000 population) was 5.40 (IQR 4.06-7.89), or 39,863 (29,971-58,244) prevalent cases. Conclusions: Disparity in rates among ALS incidence and prevalence studies may be due to differences in study design or true variations in population demographics such as age and geography, including environmental factors and genetic predisposition. Additional large-scale studies that use standardized case ascertainment methods are needed to more accurately assess the true global burden of ALS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000351153

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. [1]1. 1 Rowland LP: Amyotrophic lateral sclerosis. Curr Opin Neurol 1994; 7: 310-315.
  2. [3]3. Ng L, Talman P, Khan F: Motor neurone dis- ease: disability profile and service needs in an Australian cohort. Int J Rehabil Res 2011; 34: 151-159.
  3. [53]53. Pedro-Cuesta J, Litvan I: Epidemiology of motor neuron disease; in Anderson DW, Schoenberg DG (eds): Neuroepidemiology: A Tribute to Bruce Schoenberg. Boca Raton, CRC Press, 1991, pp 265-296.

Cited by

Sorted by citations

Authors
Chiò, A., Logroscino, G., Traynor, B. J., Collins, J., Simeone, J. C., Goldstein, L. A., & White, L. A.
Affiliations
  • University of Turin (IT)
  • University of Bari Aldo Moro (IT)
  • National Institutes of Health (US)
  • Biogen (United States) (US)
Venue
Neuroepidemiology
Publisher
S. Karger AG
Published
2013
Volume
41
Issue
2
Pages
118-130
ISSN
  • 0251-5350 (ISSN-L)
  • 1423-0208
OpenAlex
W2072204165
Cited by
862
References
78
Citations by year
2026: 49 · 2025: 52 · 2024: 64 · 2023: 85 · 2022: 80 · 2021: 97 · 2020: 89 · 2019: 61 · 2018: 79 · 2017: 64 · 2016: 64 · 2015: 42 · 2014: 28 · 2013: 6 · 2012: 1
FWCI
6.08
Type
journal article
Language
en
Open access
Locations
  • Neuroepidemiology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
Funders
  • Biogen
  • National Institutes of Health
  • National Institute on Aging (ZIAAG000933)
Topics
  • Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Amyloidosis: Diagnosis, Treatment, Outcomes
  • Health Sciences › Medicine › Genetics › Neurogenetic and Muscular Disorders Research
Keywords
amyotrophic lateral sclerosis, incidence, prevalence, global burden of disease, case ascertainment, population-based study, rare diseases, healthcare resource allocation
MeSH terms
Amyotrophic Lateral Sclerosis, Humans, Global Health

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review